First Time Loading...

AC Immune SA
NASDAQ:ACIU

Watchlist Manager
AC Immune SA Logo
AC Immune SA
NASDAQ:ACIU
Watchlist
Price: 2.96 USD -2.31% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. [ Read More ]

The intrinsic value of one ACIU stock under the Base Case scenario is 9.29 USD. Compared to the current market price of 2.96 USD, AC Immune SA is Undervalued by 68%.

Key Points:
ACIU Intrinsic Value
Base Case
9.29 USD
Undervaluation 68%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
AC Immune SA

Backtest ACIU Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ACIU stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of AC Immune SA's business.

What risks and challenges
does AC Immune SA face in the near future?

Summarize the latest earnings report
of AC Immune SA.

Provide P/E
for AC Immune SA and its competitors.

Financials

Balance Sheet Decomposition
AC Immune SA

Current Assets 125.2m
Cash & Short-Term Investments 103m
Receivables 15.7m
Other Current Assets 6.4m
Non-Current Assets 57.7m
Long-Term Investments 361k
PP&E 6.9m
Intangibles 50.4m
Current Liabilities 13.6m
Accounts Payable 1.7m
Accrued Liabilities 11.1m
Other Current Liabilities 810k
Non-Current Liabilities 8.6m
Long-Term Debt 2.8m
Other Non-Current Liabilities 5.8m
Efficiency

Earnings Waterfall
AC Immune SA

Revenue
14.8m CHF
Operating Expenses
-68.4m CHF
Operating Income
-53.6m CHF
Other Expenses
-609k CHF
Net Income
-54.2m CHF

Free Cash Flow Analysis
AC Immune SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ACIU Profitability Score
Profitability Due Diligence

AC Immune SA's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
ROIC is Increasing
Negative 3-Years Revenue Growth
27/100
Profitability
Score

AC Immune SA's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

ACIU Solvency Score
Solvency Due Diligence

AC Immune SA's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

AC Immune SA's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ACIU Price Targets Summary
AC Immune SA

Wall Street analysts forecast ACIU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ACIU is 10.71 USD with a low forecast of 6.57 USD and a high forecast of 16.8 USD.

Lowest
Price Target
6.57 USD
122% Upside
Average
Price Target
10.71 USD
262% Upside
Highest
Price Target
16.8 USD
468% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

ACIU Price
AC Immune SA

1M 1M
-18%
6M 6M
+4%
1Y 1Y
+24%
3Y 3Y
-62%
5Y 5Y
-41%
10Y 10Y
-81%
Annual Price Range
2.96
52w Low
1.85
52w High
5
Price Metrics
Average Annual Return -6.82%
Standard Deviation of Annual Returns 56.83%
Max Drawdown -83%
Shares Statistics
Market Capitalization 293.6m USD
Shares Outstanding 99 197 800
Percentage of Shares Shorted 1.03%

ACIU Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

AC Immune SA Logo
AC Immune SA

Country

Switzerland

Industry

Biotechnology

Market Cap

293.6m USD

Dividend Yield

0%

Description

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 143 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Contact

VAUD
Lausanne
EPFL Innovation Park, Building B
+41213459121.0
https://www.acimmune.com/

IPO

2016-09-23

Employees

143

Officers

Co-Founder, CEO & Director
Dr. Andrea Pfeifer Ph.D.
CFO & VP of Finance
Mr. Christopher Roberts
Chief Technical Operations Officer
Mr. Piergiorgio Donati
Chief Administrative Officer
Mr. Jean-Fabien Monin
Chief HR Officer
Mr. Howard Donovan
Chief Scientific Officer
Ms. Madiha Derouazi
Show More
Head of Investor Relations
Mr. Joshua Drumm Ph.D.
General Counsel
Mr. Alexandre Caratsch
Global Head of Communications
Judith Moore
VP of U.S. Finance & Corporate Development
Mr. Julian Snow
Show Less

See Also

Discover More
What is the Intrinsic Value of one ACIU stock?

The intrinsic value of one ACIU stock under the Base Case scenario is 9.29 USD.

Is ACIU stock undervalued or overvalued?

Compared to the current market price of 2.96 USD, AC Immune SA is Undervalued by 68%.